TGF‐β/Smads signaling pathway, Hippo‐YAP/TAZ signaling pathway, and VEGF: Their mechanisms and roles in vascular remodeling related diseases

Abstract

Vascular remodeling is a basic pathological process in various diseases characterized by abnormal changes in the morphology, structure, and function of vascular cells, such as migration, proliferation, hypertrophy, and apoptosis. Various growth factors and pathways are involved in the process of vascular remodeling. The transforming growth factor‐β (TGF‐β) signaling pathway, which is mainly mediated by TGF‐β1, is an important factor in vascular wall enhancement during vascular development and regulates the vascular response to injury by promoting the accumulation of intimal tissue. Vascular endothelial growth factor (VEGF) has an important effect on initiating the formation of blood vessels. The Hippo‐YAP/TAZ signaling pathway also plays an important role in angiogenesis. In addition, studies have shown that there is a certain interaction between the TGF‐β/Smads signaling pathway, Hippo‐YAP/TAZ signaling pathway, and VEGF. Many studies have shown that in the development of atherosclerosis, hypertension, aneurysm, vertebrobasilar dolichoectasia, pulmonary hypertension, restenosis after percutaneous transluminal angioplasty, and other diseases, various inflammatory reactions lead to changes in vascular structure and vascular microenvironment, which leads to vascular remodeling. The occurrence of vascular remodeling changes the morphology of blood vessels and thus changes the hemodynamics, which is the cause of further development of the disease process. Vascular remodeling can cause vascular smooth muscle cell dysfunction and vascular homeostasis regulation. This review aims to explore the mechanisms of the TGF‐β/Smads signaling pathway, Hippo‐YAP/TAZ signaling pathway, and vascular endothelial growth factor in vascular remodeling and related diseases. This paper is expected to provide new ideas for research on the occurrence and development of related diseases and provide a new direction for research on the treatment of related diseases.

HAX1-Overexpression Augments Cardioprotective Efficacy of Stem Cell-Based Therapy Through Mediating Hippo-Yap Signaling

“…Upon nuclear translocation, Yap can serve as a co-activator of Tead (TEA domain transcription factor) to be involved in gene transcription regulation. Experimental evidence has been documented that Yap promotes angiogenesis by regulating the expression of secreted proangiogenic proteins [38], whereas pharmacological inhibition of Yap-Tead signaling downregulated the expression level of vascular endothelial growth factor VEGF [3,33,43]. Considering these previous studies, we assessed the VEGF expression and pro-angiogenetic effects in HAX1-overexpressing CSCs.…”

Tumor-derived small extracellular vesicles in cancer invasion and metastasis: molecular mechanisms, and clinical significance

“…Vascular development may be induced by TDSEVs [9]. The most important target of angiogenesis is the VEGF/ VEGFR signaling pathway since vascular endothelial cells are essential for angiogenesis and the formation of tumors [140]. TDSEVs induce the production of VEGF by endothelial cells and upregulate VEGFR2 signaling, which leads to an increase in the expression of pro-angiogenic genes and the proliferation of endothelial cells [133].…”

Diabetes-Induced Vascular Dysfunction and Stemness Decline Investigated via Transcription Factor-Driven Genetic Switches

“…Given the crucial role of SMAD transcription factors in vascular health, targeting their regulation presents a viable therapeutic approach. Speci c inhibitors or modulators that target the TGFβ/SMAD pathway could help normalize its signaling, potentially mitigating the pathological changes induced by diabetes [149]. Given the role of SMAD in promoting brosis, anti-brotic therapies could be bene cial in managing diabetes-induced vascular complications.…”